Pharmacodynamics of Oestrogens and Progestogens

@article{deLignires2000PharmacodynamicsOO,
  title={Pharmacodynamics of Oestrogens and Progestogens},
  author={Bruno de Ligni{\`e}res and S D Silberstein},
  journal={Cephalalgia},
  year={2000},
  volume={20},
  pages={200 - 207}
}
The ovaries cyclically secrete estradiol and progesterone. Cyclic ovarian estradiol secretion is associated with a bone-saving and vascular protection effect. Endogenous progesterone does not modify the vasodilator effect of oestrogens. At physiological concentrations, the natural sex steroids have low antigonadotropic effects. More potent synthetic derivatives with more antigonadotropic effects were synthesized in the 1950s. After the menopause, there is no longer any need to use hormonal… Expand
Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception
TLDR
The molecular mechanisms of intracellular actions of old (MPA, norethisterone, levonorgestrel, gestodene) vs. new (drospirenone, dienogest, trimegestone) generation progestins, via steroid receptors are reviewed. Expand
Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women
TLDR
The transbuccal route is a novel approach to provide therapy for the management of menopause-related symptoms of postmenopausal women without the need to resort to conjugated or synthesized hormones, and may overcome the poor or erratic systemic availability associated with other routes of administration. Expand
Intranasal hormone replacement therapy.
TLDR
The intranasal route is, therefore, innovative for the delivery of natural sex steroids in postmenopausal women receiving hormone replacement therapy and demonstrates that it is safe, effective, and acceptable to post menopausal women. Expand
Headache and female hormones: what you need to know
TLDR
There is no compelling evidence that postmenopausal hormone replacement therapy either decreases or increases stroke risk and there is no contraindication to the use of oral contraceptives in women with migraine in the absence of migraine aura or other risk factors. Expand
Effect of Combined Oral Contraceptives on Breast Epithelial Proliferation in Young Women
TLDR
COC users have increased proliferative activity at the beginning of the menstrual cycle, which may relate to the increased risk of breast cancer that has been associated with COCs. Expand
Effect of estradiol-17β on serum mineral concentrations of female Japanese quail
TLDR
The aim of this study was to test the effect of E2 on serum mineral concentrations in Japanese quail (Coturnix japonica) and to establish the relationships between estradiol-17β (E2) and blood mineral levels. Expand
Oral contraceptive use and breast cancer risk: modification by NAD(P)H:quinone oxoreductase (NQO1) genetic polymorphisms.
  • J. Fowke, X. Shu, +4 authors Wei Zheng
  • Medicine
  • Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • 2004
TLDR
It is suggested that the OC and breast cancer association depends on the ability to invoke protection from catechol estrogens, and the NQO1 C609T polymorphism seems functionally relevant. Expand
Progesterone improves cognitive performance and attenuates smoking urges in abstinent smokers
TLDR
Findings suggest a potential therapeutic value of progesterone for smoking cessation and significantly improved cognitive performance in the Stroop and the Digit Symbol Substitution Test. Expand
Effect of estradiol-17β on follicle-stimulating hormone secretion and egg-laying performance of Japanese quail.
  • H. Çiftçi
  • Medicine, Biology
  • Animal : an international journal of animal bioscience
  • 2012
TLDR
Results show that serum FSH concentration was not increased even when slightly suppressed by subcutaneous injection of 0.1 or 0.2 mg E2, but it significantly increased eggshell strength probably via the increase in Ca and P utilizations. Expand
Postmenopausal hormone therapy and regional brain volumes
TLDR
Conjugated equine estrogens with or without MPA are associated with greater brain atrophy among women aged 65 years and older; however, the adverse effects are most evident in women experiencing cognitive deficits before initiating hormone therapy. Expand
...
1
2
...

References

SHOWING 1-10 OF 70 REFERENCES
Molecular mechanisms of steroid hormone action
The ability of oestrogens and androgens to stimulate the growth of a number of endocrine cancers is well established and several endocrine therapies are widely used to reduce the availability of theExpand
Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial.
TLDR
Oral estrogen/progesterone replacement therapy may result in coagulation activation and increased fibrinolytic potential, whereas opposed transdermal estrogen appears without any substantial effects on hemostasis. Expand
Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm
TLDR
It is concluded that medroxyprogesterone in contrast to progesterone increases the risk of coronary vasospasm. Expand
Pharmacology of conjugated oestrogens.
TLDR
It is possible that the sulphate group is exerting a 'protective' effect against sudden oestrogenic stimulation. Expand
Cardiovascular risk and use of estrogens or estrogen-progestagen combinations.
TLDR
The risk of cardiovascular complications from combined oral contraceptives and estrogens were assessed in 986 women from 3 Northern California communities and the effects of estrogens appeared more prevalent in Mexican-American women possibly because of their greater obesity. Expand
Progestogens and cardiovascular disease. A critical review.
  • T. Clarkson
  • Medicine
  • The Journal of reproductive medicine
  • 1999
TLDR
The attenuating effect medroxyprogesterone acetate (MPA) has on the cardiovascular benefits of postmenopausal estrogen treatment and may be largely limited to MPA and not shared with other progestogens. Expand
Effects of estrogen and progestin on aortic size and compliance in postmenopausal women.
TLDR
Estrogen therapy in postmenopausal women was associated with an increase in aortic size; but this effect was not detectable with the addition of progestin, suggesting that the favorable cardiovascular effects of post menopausal estrogen therapy cannot be automatically extended to the combination estrogen-progestin. Expand
Oral contraceptives and metabolic risk markers for coronary heart disease.
TLDR
It was concluded that reducing the progestin dose and changing the progestsin type effectively reduce the adverse impact of OCs on metabolic risk for CHD, and the use of OC formulations without adverse effects on risk profile is indicated. Expand
Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women.
TLDR
Transdermal administration of E2 to healthy postmenopausal women increases the plasma levels of NO and this supports the hypothesis that a NO-related mechanisms may contribute to the cardiovascular protective effect of estrogens in postmenopause. Expand
Transdermal estrogen replacement therapy: beneficial effects on hemostatic risk factors for cardiovascular disease.
TLDR
The increase in serum estradiol concentrations due to replacement therapy did not adversely affect the studied components of the fibrinolytic and protein C defense system against thrombosis, and resulted in beneficial decreases in F VII antigen and fibrinogen. Expand
...
1
2
3
4
5
...